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Adeno-associated virus 4 (AAV4) is one of the most divergent serotypes among known AAV isolates. Mucins or O-linked sia-
loglycans have been identified as the primary attachment receptors for AAV4 in vitro. However, little is known about the role(s)
played by sialic acid interactions in determining AAV4 tissue tropism in vivo. In the current study, we first characterized two
loss-of-function mutants obtained by screening a randomly mutated AAV4 capsid library. Both mutants harbored several amino
acid residue changes localized to the 3-fold icosahedral symmetry axes on the AAV4 capsid and displayed low transduction effi-
ciency in vitro. This defect was attributed to decreased cell surface binding as well as uptake of mutant virions. These results
were further corroborated by low transgene expression and recovery of mutant viral genomes in cardiac and lung tissue follow-
ing intravenous administration in mice. Pharmacokinetic analysis revealed rapid clearance of AAV4 mutants from the blood
circulation in conjunction with low hemagglutination potential ex vivo. These results were recapitulated with mice pretreated
intravenously with sialidase, directly confirming the role of sialic acids in determining AAV4 tissue tropism. Taken together, our
results support the notion that blood-borne AAV4 particles interact sequentially with O-linked sialoglycans expressed abun-
dantly on erythrocytes followed by cardiopulmonary tissues and subsequently for viral cell entry.
Adeno-associated viruses (AAV) are small, nonenveloped, sin-gle-strand DNA viruses (1). Numerous AAV strains have
been isolated from human and primate tissues, several of which
have been developed into gene transfer vectors due to their diverse
tissue tropisms in preclinical animal models (2). Among different
AAV clades known thus far, AAV4 is particularly unique due to its
divergent genome sequence and capsid antigenicity (3), capsid
structure (4, 5), mucin receptor usage (6, 7), and atypical systemic
(8) as well as central nervous system (CNS) tropism in mouse
models (9). Specifically, the Cap gene product of AAV4 shares
only a low homology with that of AAV2 (58%) and other prom-
inent AAV serotypes. The core structure of the AAV4 VP mono-
mer is a seven-stranded beta sheet interconnected by loop regions
as seen with other parvoviruses (4). However, the surface topology
constituted by the highly dynamic loops on the exterior of the
AAV4 capsid is strikingly distinct compared to that of other AAV
serotypes. This difference has been suggested to be the underlying
cause for the diverse phenotypes displayed by AAV serotypes with
regard to receptor usage, immunogenicity, and tissue tropism
(10, 11).
The first step in the AAV life cycle involves recognition of cell
surface glycans, which serve as primary receptors for infection
(10). Currently known glycan receptors for different AAV sero-
types include heparan sulfate (HS) for AAV2 (12), AAV3 (13, 14),
and AAV6 (15, 16); galactose (Gal) for AAV9 (17, 18); N-linked
sialic acids for AAV1 and AAV6 (19) as well as AAV5 (20); and
O-linked sialic acids or mucin for AAV4 (6, 7). Despite this wealth
of knowledge pertaining to AAV glycan receptor usage in vitro, the
influence of tissue glycosylation patterns on AAV tropism is not
well understood.
In the current study, we characterized the role(s) played by
O-linked sialylated glycans or mucins in determining the systemic
transduction profile of AAV4 in mice. We evaluated the func-
tional implications of capsid-sialic acid interactions by using a
two-pronged approach involving (i) a comprehensive evaluation
of AAV4 mutants deficient in sialic acid binding in vitro and in
vivo and (ii) enzymatic removal of tissue and cell surface sialic
acids in mice prior to virus administration. Our data support the
notion that O-linked sialoglycans play a multifaceted role that
extends beyond cell surface attachment of AAV4 and help facili-
tate cellular uptake, prolonged blood circulation half-life, and the
unique cardiopulmonary tropism of this divergent AAV serotype.
MATERIALS AND METHODS
Random mutagenesis. The AAV4 helper plasmid (pXR4) has been de-
scribed earlier (14) and was obtained from the UNC Vector Core. Ran-
dom mutations were introduced into the GH loop (amino acids 428 to
617 on AAV4 VP1; GenBank accession number U89790.1) by error-prone
PCR using the GeneMorph II EZ clone domain mutagenesis kit (Agilent
Technologies, Santa Clara, CA) as described earlier (21). Briefly, 5=-AAC
CCTCTCATCGACCAGTAC-3= and reverse primer 5=-TCCATCGGTAT
GAGGAATCTT-3= (IDT, Coralville, IA) were utilized to randomly mu-
tate and amplify regions within the Cap4 gene that encode the GH loop
region. The resulting randomized PCR product was subcloned into the
original pXR4 backbone, and individual clones were sequenced by the
UNC Genome Analysis Facility. Sequence analysis and alignments were
carried out using VectorNTI software (Invitrogen, Carlsbad, CA).
Molecular modeling. The three-dimensional structure of AAV4 was
displayed as a full icosahedral capsid or trimers using previously published
coordinates (Protein Data Bank identification code [PDB ID], 2G8G) in
PyMOL (4, 5). Homology models of the two mutants AAV4.18 and
AAV4.41 were obtained using the SWISS-MODEL online server (http:
//swissmodel.expasy.org/) (22), with the crystal structure of AAV4 VP3
(PDB ID 2G8G) serving as a template. The 3-fold symmetry axes/VP3
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trimers were generated using the oligomer generator utility in VIPERdb
(http://viperdb.scripps.edu/oligomer_multi.php) (23) and visualized
using the PyMOL Molecular Graphics System (Schrödinger, LLC, New
York, NY). Mutated residues in different capsid variants are listed in Ta-
ble 1.
Cell culture. HEK293 cells were cultured in Dulbecco’s modified Ea-
gle’s medium supplemented with 10% fetal bovine serum (FBS), 100
U/ml of penicillin, 100 g/ml of streptomycin, and 2.5 g/ml of ampho-
tericin B (Sigma-Aldrich, St. Louis, MO). CV-1 cells (African green mon-
key kidney fibroblasts) were propagated in Eagle’s minimum essential
medium with 10% FBS, 100 U/ml of penicillin, 100 g/ml of streptomy-
cin, and 2.5 g/ml of amphotericin B. Cells were maintained in 5% CO2 at
37°C unless indicated otherwise.
Virus production and titers. Recombinant AAV4 and related mu-
tants packaging reporter transgenes were generated using the triple plas-
mid transfection method described earlier (24). Briefly, the plasmids uti-
lized were the AAV4 helper, pXR4 and related Cap mutants, pXX6-80
expressing adenoviral helper genes, and pTR-CBA-Luc containing the
chicken beta-actin (CBA) promoter-driven firefly luciferase transgene
flanked by AAV inverted terminal repeats derived from the AAV2 ge-
nome. Subsequent to viral purification by gradient ultracentrifugation,
viral titers were obtained by quantitative PCR using a Roche Lightcycler
480 (Roche Applied Sciences, Pleasanton, CA). Quantitative PCR primers
were designed to specifically recognize the luciferase transgene (forward,
5=-AAA AGC ACT CTG ATT GAC AAA TAC-3=, and reverse, 5=-CCT
TCG CTT CAA AAA ATG GAA C-3=).
In vitro infectivity assays. CV-1 cells were seeded in 24-well plates at
a density of 1e5 cells/well 18 h prior to experimentation. The cells were
prechilled at 4°C for 30 min, and then AAV4, AAV4.18, or AAV4.41 pack-
aging the CBA-Luc transgene were incubated on CV-1 cell surface at 4°C
for 1 h at 1,000 genome-containing viral particles (VG)/cell, followed by
three washes with ice-cold 1 phosphate-buffered saline (1 PBS) to
remove unbound virions. To quantitate the number of cell surface-bound
virions, 200 l of double-distilled water (ddH2O) was then added to each
well and cells were subjected to three freeze-thaw cycles prior to extraction
of total genomic DNA using a DNeasy kit (Qiagen, Germantown, MD).
Viral genome titers were then determined by quantitative PCR (qPCR) as
described above. For cellular-uptake studies following removal of un-
bound virions, CV-1 cells in freshly added DMEM plus 10% FBS were
moved to a 37°C incubator to synchronize virus internalization. After an
hour, cells were treated with 150 l/well of 0.25% trypsin at 37°C for 5 min
to release cell surface-associated virions. Trypsin was then quenched by
adding 150 l/well of DMEM with 10% FBS into each well, followed by
three washes of the cell pellets with ice-cold PBS. Total genomic DNA was
then extracted as described above, and VG copy numbers were deter-
mined by qPCR. For transduction assays, CV-1 cells in freshly added
DMEM plus 10% FBS were moved to a 37°C incubator and cells lysed at 18
h posttransduction to quantitate luciferase transgene expression using a
Victor2 luminometer (PerkinElmer, Waltham, MA).
Animal studies. All animal experiments were carried out using 6- to
8-week-old female BALB/c mice purchased from Jackson Laboratories
(Bar Harbor, ME). Mice were maintained and treated in accordance with
NIH guidelines and as approved by the UNC Institutional Animal Care
and Use Committee (IACUC). To investigate the effect of sialylated gly-
cans on AAV4 tropism in vivo, BALB/c mice were injected intravenously
(i.v.) with either 400 mU/mouse of sialidase (type III, from Vibrio chol-
erae; Sigma) or 1 PBS at 3 h prior to administration of AAV4-CBA-Luc
(1e11 VG/mouse) via the same route (tail vein). To track luciferase trans-
gene expression patterns in mice at specific time points, animals were
anesthetized with 2% isoflurane prior to intraperitoneal (i.p.) injection of
D-luciferin (120 mg/kg of body weight; Nanolight, Pinetop, AZ) and im-
aged using an Xenogen IVIS Lumina system (PerkinElmer/Caliper Life
Sciences, Waltham, MA). Transduction profiles of AAV4 and related mu-
tants were determined in a similar fashion at a dose of 5e10 VG/mouse for
each viral strain injected intravenously.
To quantify luciferase expression, the same groups of mice as sub-
jected to live-animal imaging were sacrificed and different tissues har-
vested for analysis. Tissue lysates were generated by adding 150 l of 2
passive lysis buffer (Promega, Madison, WI) prior to mechanical lysis
using a Tissue Lyser II 352 system (Qiagen, Valencia, CA). Tissue lysates
were then pelleted to remove debris by centrifugation, and 50 l of the
supernatant from each lysate was subjected to luminometric analysis us-
ing a Victor2 luminometer (PerkinElmer, Waltham, MA). In addition, 2
l of supernatant was used for the Bradford assay (Bio-Rad, Hercules,
CA) to determine the protein content in each sample.
For viral biodistribution analysis, a second group of BALB/c mice were
injected with AAV4 and related mutants under different conditions and
animals sacrificed at 3 days postadministration to harvest different or-
gans. Approximately 50 mg of tissue from each organ was pretreated with
proteinase K prior to being homogenized using a Tissue Lyser as described
above. Total genomic DNA was then extracted from tissue lysates using a
DNeasy kit (Qiagen, Germantown, MD), and viral genome copy numbers
were determined by qPCR. The number of cells in each sample was quan-
tified using qPCR with primers specific to the mLamin housekeeping gene
(forward, 5=-GGA CCC AAG GAC TAC CTC AAG GG-3=, and reverse,
5=-AGG GCA CCT CCA TCT CGG AAA C-3=).
For pharmacokinetic analysis, BALB/c mice were first pretreated with
intravenous sialidase or PBS as described above. At 3 h postadministra-
tion, 1e11 VG copies of AAV4, AAV4.18, or AAV4.41-CBA-Luc were
injected through the tail vein. Ten-microliter aliquots of whole blood were
then collected by nicking the tail vein at the following time points postin-
jection: 5, 15, and 30 min and 1, 3, 6, 24, 48, and 72 h. Total DNA was then
extracted from each blood sample using a DNeasy kit, and viral genome
copy numbers were measured by qPCR.
HA assays. BALB/c mice were anesthetized using 1.25% tribromoeth-
anol (Avertin) i.p. prior to blood draws by cardiac puncture. Whole blood
was mixed with two volumes of Alsever’s solution (2.05% [wt/vol] glu-
cose, 0.8% sodium citrate, 0.055% citric acid, 0.42% sodium chloride [pH
6.1]) to prevent coagulation. Erythrocytes were collected from whole
blood by centrifugation at 2,500  g for 5 min, washed three times in 1
PBS, and diluted 10-fold in Alsever’s medium. Hemagglutination (HA)
assays were carried out in V-bottomed 96-well clear plates in a cold room
(maintained at 4°C). Briefly, AAV4, AAV4.18, or AAV4.41-CBA-Luc
(1e11 VG each) were serially diluted in 2-fold increments with 1 PBS. A
total of 50 l of 10% murine erythrocytes was then added into each well
and incubated with viral particles for 1 h. Hemagglutination titers are
expressed as the lowest viable dilutions of virus stocks.
RESULTS
Construction of the randomized AAV4 capsid library. The
3-fold symmetry axes on AAV capsids have been associated with
glycan receptor recognition in the cases of AAV2, AAV3b, AAV6,
TABLE 1 List of AAV4 mutants





AAV4.15 T496S, S515C, L564P, L588 M, R593G,
M603V, I610T
5.2e11
AAV4.18 K492E, K503E, N585S 8.6e11
AAV4.19 K479N, L501F, A569P 4.2e11
AAV4.20 T446A, S584G 7.1e11
AAV4.31 L588Q 6.6e11
AAV4.38 T463A, W514L, Q537L, G581C 2.9e11
AAV4.41 M523I, G581D, Q583E 4.3e11
AAV4.49 R593D 6.3e11
a Titers represent average vector genome copies (CBA-Luc) per ml obtained from 2 or 3
vector production runs.
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and AAV9 (25–31). The surface protrusions and spikes surround-
ing the 3-fold axes are predominantly composed of the highly
dynamic GH loop connecting the G and H strands within the
capsid protein subunit (10, 11). We have previously utilized this
approach to dissect key residues that determine AAV9 tropism
(21). To identify whether key residues within the GH loop of the
AAV4 VP3 subunit were identified in sialic acid recognition, we
generated a library of AAV4 variants by introducing random mu-
tations within this loop region. After triaging of nonviable mutant
AAV4 Cap gene constructs (containing stop codons, deletions, or
frameshift mutations), 48 clones were arbitrarily chosen for fur-
ther structural modeling and comparative analysis with the orig-
inal AAV4 capsid template. Subsequently, several AAV4 mutants
were selected on the basis of the predominance of mutations at
surface-exposed sites for further characterization (Fig. 1 and Table
1). The mutations represented by this collection of AAV4 variants
are clustered around the surface of the capsid region surrounding
the 3-fold symmetry axes (highlighted in blue in Fig. 1). Variation
in vector genome titers for different mutants was found to be
within 3-fold or less compared to that of parental AAV4 vectors,
indicating that the different mutations within this subset did not
affect capsid stability or genome packaging efficiency (Table 1). A
detailed characterization of two loss-of-function mutants,
AAV4.18 (K492E, K503E, and N585S) and AAV4.41 (M523I,
G581D, and Q583E), is described herein.
Mutant AAV4 strains are transduction-deficient in mice fol-
lowing systemic administration. Intravenous (i.v.) administra-
tion of AAV4 vectors in mice results in selective cardiopulmo-
nary transgene expression (8). Screening of different mutant
AAV4 strains following i.v. injection in mice was carried out by
bioluminescent imaging and monitoring of luciferase trans-
gene expression (Fig. 2A and B). At 1 month postadministra-
tion (Fig. 2A), AAV4 mutants display two types of tissue trans-
duction profiles in comparison with that of the parental AAV4.
While the majority of the mutants demonstrate transduction
efficiency similar to that of AAV4, both AAV4.18 and AAV4.41
exhibit decreased luciferase activity in the upper thoracic re-
gion. Specifically, as shown in Fig. 2C, in the case of AAV4.18,
cardiac transduction decreased by more than 2 orders of mag-
nitude, while transgene expression levels in the lung were de-
creased by 1 log unit compared to those of AAV4. In case of
AAV4.41, a more dramatic loss in transduction efficiency was
observed in lung tissue (2 log units) compared to cardiac
FIG 1 Three-dimensional models of the AAV4 capsid library and capsid subunit trimers. Three-dimensional structural models of an intact AAV4 capsid in red (A) with
the capsid subunit trimer/3-fold symmetry axis region comprised of the loop regions connecting G and H beta-strands (VP1 numbering, 428 to 617) highlighted in blue
(B) are shown. (C) A collection of AAV4 mutations represented within the randomized capsid library with surface-exposed residues highlighted in blue on the AAV4
trimer. Specific residues and point mutations are listed in Table 1. Structural models were visualized and generated using PyMOL.
FIG 2 Transduction profiles of AAV4 mutants in vivo. (A) Parental AAV4 and
different AAV4 mutants packaging the CBA-Luc transgene were injected in-
travenously into BALB/c mice (5e10 VG/mouse). At 1 month postinjection,
live-animal bioluminescent images were obtained using a Xenogen IVIS Lu-
mina system (n  3). Scales represents relative light units (RLU) as photons
per second per cm2 per steradian. (B) Mice were sacrificed at 1 month postad-
ministration to harvest different organs, and luciferase expression in different
tissues was quantified using a Victor 2 bioluminescence plate reader. Data
(RLU) are shown as means  SEMs (n  4). (C) Detailed analysis of luciferase
transgene expression of AAV4, AAV4.18, and AAV4.41 in mice at 1 month
postadministration. (D) Vector genome biodistribution of AAV4, AAV4.18,
and AAV4.41 in BALB/c mice at 3 days postadministration. Viral genome copy
numbers were obtained using qPCR and normalized to mouse lamin genes
(host genomic DNA) copy numbers. Data are plotted as means  SEMs (n 
4). Statistical significance was analyzed using the one-tailed Student t test (*,
P 	 0.05; **, P 	 0.01; n.s., not significant).
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tissue (1 log unit). These results were further corroborated by
decreased accumulation of mutant virions in cardiac and lung
tissue compared to that of AAV4 particles (Fig. 2D). Specifi-
cally, AAV4.18 and AAV4.41 displayed 5- to 10-fold de-
creases in viral genome copy numbers in these tissues, consis-
tent with decreased cardiopulmonary transduction observed
earlier. The transduction efficiency and sequestration of mu-
tant AAV4 strains within the liver remained largely unaffected.
Mutants AAV4.18 and AAV4.41 are deficient in cell surface
binding and uptake in vitro. Consistent with the in vivo charac-
terization, AAV4.18 and AAV4.41 also showed a transduction-
deficient phenotype in African green monkey kidney fibroblasts
(CV-1). As seen in Fig. 3A, luciferase transgene expression levels
mediated by the two mutants are 1 log unit lower than that of
parental AAV4 in CV-1 cells. Viral binding and internalization
assays revealed that both AAV4.18 and AAV4.41 display 25 to 50%
lower binding on CV-1 cells (Fig. 3B, gray bars). Further, cellular
uptake of the two mutant strains appears to be significantly im-
paired (10-fold lower) compared to that of AAV4 (Fig. 3B, white
bars). While nearly 40% of surface-bound AAV4 particles appear
to be internalized after 1 h of incubation, only 10 to 20% of mutant
virions are internalized (Fig. 3C). Taken together, these results
suggest that the transduction-deficient phenotype displayed by
mutants AAV4.18 and AAV4.41 is likely due to decreased cell
surface binding as well as defective uptake in vitro. In corrobora-
tion with in vivo analysis, this decreased cell surface binding fur-
ther results in loss of function in transducing the cardiopulmo-
nary system in animals.
Intravenous sialidase treatment abrogates cardiopulmonary
transduction by AAV4. A critical issue that follows the transduc-
tion-defective phenotype of AAV4.18 and AAV4.41 mutants de-
scribed above is whether this phenotype can be attributed to defi-
cient sialoglycan interactions in vivo. In order to address this
question, we preadministered recombinant sialidase intrave-
nously to remove surface-exposed sialic acid moieties from major
organs. Our laboratory has demonstrated previously that expo-
sure of terminal galactose in different tissues is significantly in-
creased upon such enzymatic removal of sialic acids (32). As seen
in Fig. 4A, the characteristic bioluminescent signal observed due
to AAV4-mediated luciferase transgene expression in the upper
thoracic region is markedly decreased in sialidase-pretreated
mice. This observation was corroborated by quantitation of lucif-
erase expression in the heart and lung, which show nearly 300- to
600-fold-lower transgene expression levels in the sialidase-treated
group versus the PBS-treated control (Fig. 4B). Transgene expres-
sion within the liver is marginally increased upon enzymatic re-
moval of sialic acid. Quantitative analysis of viral genome copy
numbers in heart, lung, and liver revealed a biodistribution profile
consistent with transduction. Specifically, an approximately 250-
to 400-fold decrease in viral genome copy number within cardiac
and pulmonary tissues is observed in sialidase-treated mice, while
no significant changes were noted in hepatic tissue (Fig. 4C).
These results revealed a functional role for sialic acids in determin-
ing AAV4 transduction in vivo and further help clarify the defec-
tive phenotype displayed by AAV4 mutants.
Cardiopulmonary tropism of AAV4 correlates with tissue
expression of O-linked sialoglycans. To specifically establish the
role of O-linked sialic acids in determining the unique cardiopul-
monary tropism displayed by AAV4, we carried out lectin immu-
nostaining to determine expression of O-linked sialic acids within
the murine heart, lung, and liver. Briefly, sections of heart, lung,
and liver from mice underwent immunostaining using fluorescein
isothiocyanate (FITC)-labeled jacalin, a lectin isolated from
jackfruit (Artocarpus integrifolia) (33) that specifically recog-
nizes O-linked oligosaccharides, i.e., mucins. As shown in Fig.
4D, FITC-jacalin shows a markedly higher staining in the cili-
ated mouse airway epithelial lining and alveoli. Robust staining
is also observed in cross sections of the murine heart. In con-
trast, robust FITC-jacalin is noted primarily in the endothelial
wall lining blood vessels within hepatic tissue. Taken together
with the transduction and biodistribution profile of blood-
borne AAV4, these data strongly support a critical role for O-
linked sialic acids in determining the selective cardiopulmo-
nary tropism of AAV4.
FIG 3 Infectivity, binding, and internalization assays of AAV4, AAV4.18, and AAV4.41 on CV-1 cells. (A) Infectivity of AAV4, AAV4.18, and AAV4.41 on CV-1
cells. AAV4, AAV4.18, and AAV4.41-CBA-Luc (MOI  1,000 VG/cell) were incubated on prechilled CV-1 cells for 1 h prior to three washes with 1 PBS to
remove unbound viral particles. Cells were lysed 18 h postinfection to quantify luciferase transgene expression using a bioluminescence plate reader. Data are
presented as means  SEMs (n  4). (B) Binding (gray bars) and internalization (white bars) of AAV4, AAV4.18, and AAV4.41 on CV-1 cells. Cells were infected
as described above and lysed after the wash step to quantify numbers of bound virions using qPCR or moved to a 37°C incubator to allow cellular uptake. At 1
h after incubation at 37°C, surface-bound virions were removed by trypsin and trypsin-resistant viral particles associated with CV-1 cells were quantified using
qPCR. Data are shown as means  SEMs (n  4). (C) Percentage of internalization of AAV4, AAV4.18, and AAV4.41. The amount of internalized virions was
normalized to the amount of bound virions for AAV4 and mutants to quantify their internalization efficiency in CV-1 cells. Statistical significance was analyzed
using the one-tailed Student t test (*, P 	 0.05).
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Mutant AAV4 virions and sialidase pretreatment are subject
to faster blood clearance in mice. To understand the impact of
AAV4-sialic acid interactions on pharmacokinetics, we first quan-
titated the number of circulating mutant and parental AAV4
strains following a single intravenous bolus injection using quan-
titative PCR. As shown in Fig. 5A, over a 72-h period, we observed
striking differences in the blood circulation profiles of parental
and mutant AAV4 virions. Both AAV4.18 and AAV4.41 mutants
were adversely affected and displayed rapid elimination from the
blood as early as 6 h postadministration. Further, we recovered
low blood levels of the AAV4.18 and AAV4.41 mutants at 24, 48,
and 72 h postinjection. The AAV4.41 mutant was more pro-
foundly deficient and displayed accelerated blood clearance com-
pared to the AAV4.18 mutant. In contrast, the parental AAV4
strain appears to persist longer in the blood circulation, with de-
tectable genomes over a 72-h period. The defective phenotype of
AAV4 mutants was further corroborated by intravenous pretreat-
ment with recombinant sialidase, which accelerated the clearance
of parental AAV4 particles between the 24- and 72-h intervals
(Fig. 5B). Taken together, these results support the notion that
interactions between the AAV4 capsid and sialoglycans influence
FIG 4 Cardiopulmonary tropism of AAV4 is dependent on sialic acid expres-
sion. (A) Live-animal images of AAV4-mediated luciferase transgene expres-
sion in BALB/c mice. Mice (n  4) were injected with PBS or sialidase from
Vibrio cholerae (400 mU/mouse) through the tail vein 3 h prior to AAV4-CBA-
Luc (1e11 VG/mouse) injection via the same route. At 7 days postinfection,
live-animal bioluminescence images were recorded with a Xenogen IVIS Lu-
mina imaging system. Scale indicates relative light units (RLU) as photons per
s per cm2 per steradian. (B) Luciferase transgene expression in tissue lysates at
7 days postadministration. At 3 h prior to AAV4-CBA-Luc injection, PBS or
sialidase was injected intravenously into BALB/c mice (n  4). At 7 days
postinfection, different organs were harvested. Luciferase transgene expres-
sion in each tissue lysate was measured using a bioluminescence plate reader.
Values are expressed in RLU normalized to amount of protein in each lysate
sample. Data are shown as means  SEMs (n  4). (C) Biodistribution of
AAV4 viral genomes in BALB/c mice. Vector and host genomic DNA in tissue
lysates was isolated and subjected to quantitative PCR analysis, as described in
Materials and Methods. Viral genome copies were normalized to copy num-
bers of the mouse lamin gene. Data are shown as means  SEMs (n  4).
Statistical significance was analyzed using the one-tailed Student t test (*, P 	
0.05; **, P 	 0.01; n.s., not significant). (D) Lung, heart, and liver tissues
harvested from BALB/c mice were stained with FITC-jacalin, a lectin specific
to O-linked polysaccharides. Confocal micrographs were obtained using a
Zeiss 710 confocal laser scanning microscope with a 20 objective at zoom 0.6.
Scale bar  100 m.
FIG 5 Sialic acid determines the blood circulation profile of AAV4. (A) Pa-
rental AAV4 and mutants AAV4.18 and AAV4.41 (1e11 VG/mouse) were ad-
ministered into BALB/c mice via intravenous injections. Approximately 10 l
of blood was collected through tail vein nicks at following times postinjection:
5 min, 15 min, 30 min, 1 h, 3 h, 6 h, 24 h, 48 h, and 72 h. Viral genome copy
numbers in each blood sample were quantified using qPCR with primers
against the luciferase transgene. Data are shown as means  SEMs (n  4). (B)
Kinetics of AAV4 clearance from blood was determined over 72 h postadmin-
istration with or without sialidase pretreatment. At 3 h prior to AAV4 vector
administration, recombinant sialidase from Vibrio cholerae (400 mU/mouse)
or PBS (control) was intravenously injected into BALB/c mice (n  4). Ap-
proximately 10 l of blood was collected from tail vein nicks at intervals sim-
ilar to those for panel A. Viral genome copies in blood samples were quantified
using qPCR, and data are shown as means  SEMs (n  4).
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not only cellular uptake, tissue tropism, and transduction effi-
ciency but also the prolonged blood residence time of systemically
administered viral particles.
Mutant AAV4 virions are deficient in hemagglutination.
Lastly, we carried out hemagglutination assays with mutant and
parental strains to determine whether direct AAV4 capsid-eryth-
rocyte interactions might influence blood clearance rates. Consis-
tent with earlier observations (6), AAV4 has a high HA titer
(128), indicating a high binding affinity toward sialoglycans on
the surface of murine erythrocytes. However, as shown in Table 2,
both AAV4.18 and AAV4.41 display low HA titers (4) similar to
those of PBS and AAV2 vectors, which were included as controls
and do not hemagglutinate murine erythrocytes. These results
confirm the notion that the AAV4 mutants described in this re-
port are defective in sialoglycan interactions.
DISCUSSION
Sialylated glycans function as cellular attachment receptors for
several viruses, including influenza virus, rotaviruses, coxsackievi-
ruses, etc. (34, 35). For instance, pathogenic respiratory viruses,
such as influenza viruses and rhinoviruses, recognize specialized
forms of sialic acids on upper airway epithelial cells to infect their
corresponding hosts (36, 37). Hepatitis B, C, and E viruses employ
heparan sulfates, which are abundant on hepatocytes, to infect
human liver (38–40). In the Dependovirus genus of the Parvoviri-
dae family, AAV4 is the only serotype known thus far to bind
O-linked sialic acids. Previous studies have demonstrated that api-
cal transduction of well-differentiated human airway epithelial
cells by AAV4 is effectively inhibited by secreted mucins and O-
linked sialoglycans (7). In contrast, AAV4 efficiently transduces
airway epithelia from the basolateral side in a sialic acid-depen-
dent fashion. Given these strong interactions with mucins in vitro
and the selective cardiopulmonary tropism of systemically admin-
istered AAV4 in vivo (8), we explored the role of O-linked sialogly-
cans in determining the tissue tropism of this divergent serotype.
First, we successfully demonstrated the applicability of a pre-
viously established, random library approach developed in our
laboratory (21) to discover new loss-of-function AAV4 mutants
that are presumably defective in sialic acid recognition. For in-
stance, key basic residues (R484, R487, K532, R585, and R588)
involved in heparan sulfate recognition have now been located on
3-fold protrusions of the AAV2 capsid (25, 27, 29, 41). Similarly,
heparan sulfate recognition by AAV3B and AAV6 capsids is now
well established (26, 28, 31). In the case of AAV9, the residues
D271, N272, N470, Y446, and W503 are required for Gal binding
(30). Unlike heparan sulfate or galactose, the binding site(s) or key
residues involved in sialic acid recognition are yet to be identified
for the corresponding AAV strains. Our results support the notion
that several amino acids (K492, K503, M523, G581, Q583, and
N585) located on the surfaces of AAV4.18 and AAV4.41 mutant
capsids might represent a subset of key residues that might directly
or indirectly influence sialic acid recognition by AAV4 capsids. It
is interesting that two of these residues, K492 and K503, lie within
the hypervariable region (HVR) IV, while three others, G581,
Q583, and N585, lie within HVR VIII. Both of these surface loops
have been implicated in the formation of the 3-fold peaks on the
AAV capsid and contain key amino acids implicated in glycan
binding for other serotypes (4). As mentioned earlier, W503 in
HVR IV is a key residue in the Gal binding pocket of the AAV9
capsid, while R585 and R588 in HVR VIII have been implicated in
heparan sulfate binding by AAV2 capsids. While the exact struc-
tural contribution of these residues remains to be determined,
these loss-of-function mutants confirm that the sialic acid binding
footprint on AAV4 capsids likely lies within the surface loops sur-
rounding the 3-fold symmetry axes. Although the current study
highlights a critical role for the above-listed residues in cell surface
binding and uptake, it should be noted that these residues might
also influence other postentry steps, such as capsid uncoating.
However, these aspects of the AAV4 infectious pathway were out-
side the scope of the current study.
A key observation is that sialic acids not only are involved in
cell surface attachment but also are essential for cellular uptake of
AAV4 capsids in CV-1 cells in vitro. This scenario is unique and
does not appear to be the case for other AAV serotypes that rec-
ognize N-linked sialic acid. For instance, platelet-derived growth
factor receptor (PDGFR) and epidermal growth factor receptor
(EGFR) have been identified as coreceptors for AAV5 and AAV6,
respectively (42, 43). However, a putative coreceptor involved in
the cellular uptake of AAV4 has yet to be determined. It is also
interesting that the conserved integrin binding motif (NGR) re-
ported for several AAV serotypes is mutated (DGR) on AAV4
capsids (44). In light of these observations, it is tempting to spec-
ulate that O-sialylated glycans might be directly involved in the
cellular uptake of AAV4 particles, unlike for other AAV serotypes.
We disrupted AAV4-sialic acid interactions in vivo using two
complementary strategies, i.e., loss-of-function mutants and in-
travenous sialidase pretreatment of mice. Both strategies pro-
foundly impact AAV4 tropism by abrogating the native cardiopul-
monary transduction profile observed in mice following systemic
administration. Further, we observed marked changes in the
pharmacokinetic profile under these conditions. Based on these
results, we propose a sequential interaction between systemically
administered AAV4 particles with circulating erythrocytes fol-
lowed by the cardiopulmonary system, both of which abundantly
express O-sialoglycans. A similar paradigm has been postulated
for adenoviruses recognizing sialic acids and the cell adhesion
molecule CAR on erythrocytes (45). Specifically, in the study re-
ported in reference 45, adenoviral binding to CAR on erythrocytes
was demonstrated to prolong the circulation half-life and reduce
liver tropism. Further, our laboratory and others have recently
demonstrated that the systemic tropism displayed by AAV9 is as-
sociated with prolonged blood circulation and glycan binding
avidity (32, 46).
Our study raises several important questions pertinent to dis-
secting the cellular, tissue-selective, and host-specific tropism(s)
of AAV serotype 4. For instance, a disproportionate decrease in
viral genome copy number was observed for AAV4.18 in cardiac
tissue compared to that for wild-type AAV4 (Fig. 2C and D). This
is an interesting observation, since in vitro data suggest that defi-
ciencies in binding and cellular uptake sufficiently explain the
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transduction defect for this mutant. One possible explanation is
that AAV4 particles associated with serum proteins are bound,
internalized, or cleared from the circulation by vascular endothe-
lium through nonspecific uptake pathways that do not result in
productive transduction. Another possible explanation is the like-
lihood that the kinetics of binding and tissue uptake in vivo differ
from those observed in vitro. It is likely that a time course study of
viral genome accumulation in different organs might yield a better
correlation between vector genome copy number and transduc-
tion efficiency in different organs. Lastly, it is also likely that the
capsid mutations could affect postentry trafficking events such as
capsid uncoating.
Another intriguing question is whether the loss-of-function
mutations reported in the current study alter the cellular tropism
of AAV4 within peripheral tissues lacking erythrocytes, such as the
eye and the brain. Another critical question is whether the host-
specific tropism of recombinant AAV4 vectors is likely to vary
with O-linked sialylation patterns observed in different species. In
this regard, screening of AAV vectors in multiple preclinical ani-
mal models and mapping the glycosylation patterns of different
host tissues might be critical to interpreting or predicting clinical
outcomes. In summary, our study provides new insights into the
biology of AAV serotype 4. The results described are likely to help
us better understand virus-glycan interactions in general as well as
guide the selection of appropriate preclinical models for studying
virus-host interactions.
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